Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A P2Y12
inhibitor under investigation as anantiplatelet drug forintravenous application.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word cangrelor.
Examples
-
Medicines Co. lost 4.12, or 37%, to 7.02, as the pharmaceutical company said it is discontinuing its Phase III "Champion" clinical trial of cangrelor in patients undergoing percutaneous coronary intervention.
-
TMC is currently spending about $100m on R&D, 60% of which is dedicated to cangrelor and oritavancin, according to TMC's latest quarterly report.
unknown title 2011
-
Licensed from Astra in 2003, TMC had to ditch a pivotal 15,000 patient trial programme for cangrelor in 2009 as the drug failed to show any advantage over gold standard antiplatelet drug .
unknown title 2011
-
However, TMC continues to see potential in cangrelor, particularly as an agent which can be used in patients that have to stop taking Plavix ten days prior to cardiac surgery due to its short half-life.
unknown title 2011
-
As for the late stage pipeline, TMC is pushing on with the development of cangrelor, a platelet aggregation inhibitor in the same class as .
unknown title 2011
-
Although the potential of cangrelor and oritavancin is clear, the key caveat here is 'potential,' given the big clinical and regulatory challenges both products still face.
unknown title 2011
-
The company increased research and development spending to $26.5 million, from $20.6 million a year earlier, with the blood drug cangrelor, and the antibiotic oritavancin, in late-stage clinical trials.
unknown title 2011
-
Harrington et al. 1 and Bhatt et al. 2 (Dec. 10 issue) describe the results of studies of platelet inhibition with intravenous cangrelor in patients undergoing percutaneous coronary intervention (PCI).
-
Harrington et al. 1 and Bhatt et al. 2 (Dec. 10 issue) describe the results of studies of platelet inhibition with intravenous cangrelor in patients undergoing percutaneous coronary intervention (PCI).
-
Harrington et al. 1 and Bhatt et al. 2 (Dec. 10 issue) describe the results of studies of platelet inhibition with intravenous cangrelor in patients undergoing percutaneous coronary intervention (PCI).
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.